|Bid||16.00 x 1200|
|Ask||16.14 x 900|
|Day's Range||15.83 - 16.49|
|52 Week Range||15.79 - 20.42|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SEATTLE, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the closing of its initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $204.0 million. Athira’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “ATHA” on September 18, 2020. In addition, Athira has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of Athira’s common stock at the initial public offering price less the underwriting discounts and commissions. Goldman Sachs & Co. LLC, Jefferies and Stifel are acting as joint book-running managers for the offering. JMP Securities is acting as co-manager for the offering.Registration statements relating to the shares being sold in the offering were filed with the Securities and Exchange Commission (the “SEC”) and became effective on September 17, 2020. The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at email@example.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at firstname.lastname@example.org.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.Media Contacts: David Schull or Maggie Beller Russo Partners LLC David.email@example.com Maggie.firstname.lastname@example.org 646-942-5631Investor Contact: Sarah McCabe Stern Investor Relations, Inc. email@example.com 212-362-1200
Shares of Athira Pharma Inc. rallied in their public debut, as the first trade was 17.4% above the initial public offering price. The Seattle-based biopharmaceutical company's upsized IPO priced late Thursday at $17 share, at the top of the expected range of $15 to $17 a share. The stock's first trade on the Nasdaq was at $19.95 at 12.01 p.m. Eastern for 7,69,298 shares. The company sold 12 million shares in the IPO, up from previous expectations of 10 million shares, to raise $204 million. The company was valued at about $489.8 million at the IPO price. The stock has pulled back since it opened, to trade up just 1.6%. Athira's public debut comes at the end of a busy week for IPOs, which was highlighted by Snowflake Inc.'s red-hot debut earlier this week. The Renaissance IPO ETF has rallied 20.1% over the past three months, while the S&P 500 has gained 7.3%.
Dr. Leen Kawas, Athira Pharma CEO, joins Yahoo Finance’s The First Trade with Alexis Christoforous and Brian Sozzi to discuss Athira's debut on the Nasdaq, diversity at the company, and much more.